ACIP COVID-19 Public Statement

ACIP COVID-19 Public Statement

NEW YORK and MAINZ, GERMANY, SEPTEMBER 19, 2025 - Over the past five years, Pfizer and BioNTech's COVID-19 vaccine efforts reflect a continuous commitment to address a public health challenge. The Pfizer and BioNTech COVID-19 vaccine, with over 5 billion doses distributed globally, has consistently demonstrated a favorable safety and efficacy profile. Randomized clinical trials, real-world effectiveness studies and global pharmacovigilance confirm the vaccine helps prevent COVID-19 related hospitalizations, severe illness, and death.

More than 600 peer-reviewed publications and ongoing safety surveillance have documented the performance of the vaccine, and these data, which we are continuing to share publicly, reflect the enduring dedication to the safety and effectiveness of the COVID-19 vaccine.

Pfizer and BioNTech will continue to pursue transparency, accountability, and are committed to scientific integrity and public health.

About Pfizer: Breakthroughs That Change Patients' LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at https://www.Pfizer.com. In addition, to learn more, please visit us on https://www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Contacts

Pfizer:
Media Relations
+1 (212) 733-1226
[email protected]

Investor Relations
+1 (212) 733-4848
[email protected]

BioNTech:
Media Relations
Jasmina Alatovic
[email protected]

Investor Relations
Douglas Maffei, Ph.D.
[email protected]

# # #

• Covid-19